The goals of the InMediValue project are:
– the successful development of a pain-reduced 3D mammography examination procedure to achieve a higher quality and participation rate in breast cancer screening
– the successful development of artificial intelligence-based technology for 3D mammography image analysis to improve the analysis of calcium deposition patterns in radiological reporting
– the successful development of a imaging marker to enable surgeons to localize involved lymph nodes or tumors using innovative imaging techniques.
Demandoriented, practical problems from the field of medical imaging, e.g. from the university hospital as a user were addressed in order to develop solutions in cooperation with the universities and the companies involved. The participating research institutions and companies develop and protect innovative solutions and findings in order to be able to offer them in the short, medium and long term for the benefit of patients. In addition, the products of the participating companies currently being developed are to be brought to market maturity and made accessible across borders for the performance and evaluation of mammography examinations.
The project partners have already achieved very good cross-border successes in the consortium, which cooperates excellently, and are convinced that the ambitious goals of the InMediValue project will be achieved by the end of the project.
1.10.2018 - 30.9.2022
Increase of cross-border innovation in the programme area
TAFH Münster GmbH, Cysal GmbH, Sigmascreening BV, ScreenPoint Medical BV, MIRA-Institut, Universität Twente, Institut für Klinische Radiologie, Holland Innovative,
|Institut für Klinische Radiologie||109.622,02 €|
|Holland Innovative||103.699,49 €|
|ScreenPoint Medical BV||333.938,49 €|
|MIRA-Institut, Universität Twente||95.789,25 €|
|Provincie Gelderland||40.655,80 €|
|Cysal GmbH||65.268,48 €|
|Ministerie van Economische Zaken en Klimaat||182.951,00 €|
|Fachhochschule Münster||303.177,30 €|
|EFRE / EFRO||1.718.919,00 €|
|TAFH Münster GmbH||220,28 €|
|Sigmascreening BV||156.616,17 €|
|MWIDE NRW||304.918,00 €|
|Provincie Overijssel||81.311,60 €|